Sewickley native Miguel Regueiro, M.D., has been named chair of Cleveland Clinic’s Digestive Disease & Surgery Institute. “Dr. Regueiro’s leadership and focus align with our mission of caring for life, researching for health, and educating those who serve,” said Cleveland Clinic’s Chief of Staff Beri Ridgeway, M.D. “His dedication to
The FDA has issued an emergency use authorization for the monoclonal antibody sotrovimab to treat mild-to-moderate COVID-19 in patients at risk for progressing to severe disease, according to a press release.
The emergency use authorization — now the third for a monoclonal antibody in the treatment of COVID-19 — is specifically for adults and children aged 12 years and older who weigh
Dr. Miguel Regueiro has been named to the position, succeeding Dr. Matthew Walsh, who had served as interim chair since October. Walsh will continue his role as chair of the Department of General Surgery.
Influenza Insights: When Flu Strikes Patients With Rheumatic Diseases
Influenza Insights: When Flu Strikes Patients With Rheumatic Diseases
1.25 CME 75
MINS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Subscribe
ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Back to Healio
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Back to Healio
Support Statement
Activity Description
Influenza places a substantial burden on the health of both children and adults in the United States each year. Although immunization helps to prevent flu infection, there is a need for improved diagnostics, treatments, and preventive measures, especially in high-risk patients who have comorbid illnesses or who are immunocompromised. Pat
Operator
Good morning, and welcome to the Iveric Bio first-quarter 2021 earnings conference call. [Operator instructions] Please note this call is being recorded. I would now like to turn the conference over to Kathy Galante, senior vice president, investor relations. Please go ahead.
Kathy Galante
Senior Vice President, Investor Relations
Good morning, and welcome to Iveric Bio s conference call. Representing Iveric Bio today are Glenn Sblendorio, chief executive officer; Pravin Dugel, president; David Carroll, chief financial officer; Dhaval Desai, chief development officer; Abraham Scaria, chief scientific officer; and Keith Westby, chief operating officer. I would like to remind you that today, we will be making statements relating to Iveric Bio s future expectations regarding operational, financial and research and development matters, including statements regarding our expectations for patient enrollment and patient retention in GATHER2, our second Phase 3 clinical trial